Berry Genomics Co Ltd (000710) - Total Assets
Based on the latest financial reports, Berry Genomics Co Ltd (000710) holds total assets worth CN¥2.34 Billion CNY (≈ $342.96 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Berry Genomics Co Ltd's book value for net asset value and shareholders' equity analysis.
Berry Genomics Co Ltd - Total Assets Trend (1994–2024)
This chart illustrates how Berry Genomics Co Ltd's total assets have evolved over time, based on quarterly financial data.
Berry Genomics Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Berry Genomics Co Ltd's total assets of CN¥2.34 Billion consist of 60.4% current assets and 39.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.1% |
| Accounts Receivable | CN¥771.17 Million | 32.3% |
| Inventory | CN¥194.91 Million | 8.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥61.83 Million | 2.6% |
| Goodwill | CN¥13.43 Million | 0.6% |
Asset Composition Trend (1994–2024)
This chart illustrates how Berry Genomics Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Berry Genomics Co Ltd (000710) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Berry Genomics Co Ltd's current assets represent 60.4% of total assets in 2024, a decrease from 71.5% in 1994.
- Cash Position: Cash and equivalents constituted 16.1% of total assets in 2024, up from 15.4% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is accounts receivable at 32.3% of total assets.
Berry Genomics Co Ltd Competitors by Total Assets
Key competitors of Berry Genomics Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.17 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Fleury S.A.
SA:FLRY3
|
Brazil | R$13.22 Billion |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
China | CN¥2.43 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.17 Million |
|
Avricore Health Inc
V:AVCR
|
Canada | CA$1.33 Million |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
Berry Genomics Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.49 | 2.70 | 3.61 |
| Quick Ratio | 2.14 | 2.37 | 3.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥777.02 Million | CN¥1.00 Billion | CN¥1.45 Billion |
Berry Genomics Co Ltd - Advanced Valuation Insights
This section examines the relationship between Berry Genomics Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.68 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | -13.0% |
| Total Assets | CN¥2.38 Billion |
| Market Capitalization | $516.80 Million USD |
Valuation Analysis
Below Book Valuation: The market values Berry Genomics Co Ltd's assets below their book value (0.22x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Berry Genomics Co Ltd's assets decreased by 13.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Berry Genomics Co Ltd (1994–2024)
The table below shows the annual total assets of Berry Genomics Co Ltd from 1994 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.38 Billion ≈ $348.96 Million |
-13.00% |
| 2023-12-31 | CN¥2.74 Billion ≈ $401.12 Million |
-14.36% |
| 2022-12-31 | CN¥3.20 Billion ≈ $468.39 Million |
-9.06% |
| 2021-12-31 | CN¥3.52 Billion ≈ $515.05 Million |
+8.50% |
| 2020-12-31 | CN¥3.24 Billion ≈ $474.69 Million |
+5.71% |
| 2019-12-31 | CN¥3.07 Billion ≈ $449.07 Million |
+40.90% |
| 2018-12-31 | CN¥2.18 Billion ≈ $318.71 Million |
+20.57% |
| 2017-12-31 | CN¥1.81 Billion ≈ $264.33 Million |
+229.61% |
| 2016-12-31 | CN¥548.04 Million ≈ $80.20 Million |
+9.85% |
| 2015-12-31 | CN¥498.88 Million ≈ $73.00 Million |
+11.89% |
| 2014-12-31 | CN¥445.85 Million ≈ $65.24 Million |
+8.72% |
| 2013-12-31 | CN¥410.08 Million ≈ $60.01 Million |
+20.25% |
| 2012-12-31 | CN¥341.02 Million ≈ $49.90 Million |
-4.00% |
| 2011-12-31 | CN¥355.23 Million ≈ $51.98 Million |
-7.32% |
| 2010-12-31 | CN¥383.27 Million ≈ $56.08 Million |
+4.70% |
| 2009-12-31 | CN¥366.05 Million ≈ $53.56 Million |
+17.60% |
| 2008-12-31 | CN¥311.28 Million ≈ $45.55 Million |
+37.71% |
| 2007-12-31 | CN¥226.04 Million ≈ $33.08 Million |
-7.61% |
| 2006-12-31 | CN¥244.65 Million ≈ $35.80 Million |
+4.62% |
| 2005-12-31 | CN¥233.85 Million ≈ $34.22 Million |
-16.04% |
| 2004-12-31 | CN¥278.52 Million ≈ $40.76 Million |
+7.78% |
| 2003-12-31 | CN¥258.41 Million ≈ $37.81 Million |
+6.74% |
| 2002-12-31 | CN¥242.10 Million ≈ $35.43 Million |
-32.24% |
| 2001-12-31 | CN¥357.29 Million ≈ $52.28 Million |
+7.49% |
| 2000-12-31 | CN¥332.39 Million ≈ $48.64 Million |
+11.29% |
| 1999-12-31 | CN¥298.68 Million ≈ $43.71 Million |
-2.96% |
| 1998-12-31 | CN¥307.78 Million ≈ $45.04 Million |
+6.16% |
| 1997-12-31 | CN¥289.91 Million ≈ $42.42 Million |
+45.62% |
| 1996-12-31 | CN¥199.09 Million ≈ $29.13 Million |
+45.80% |
| 1995-12-31 | CN¥136.55 Million ≈ $19.98 Million |
+36.05% |
| 1994-12-31 | CN¥100.36 Million ≈ $14.69 Million |
-- |
About Berry Genomics Co Ltd
Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor genetic testing, NextSeq CN500 gene sequencer, and laboratory solutions. It also provides technology services, such as human genome sequencing, transcri… Read more